Early Endosome Disturbance and Endolysosomal Pathway Dysfunction in Duchenne Muscular Dystrophy.

Area of Science:

• Muscle biology
• Cellular pathology
• Genetic disorders

Background:

• Duchenne muscular dystrophy (DMD) is a fatal genetic disorder.
• DMD involves progressive muscle fiber loss due to DMD gene mutations and dystrophin absence.
• Previous research noted autophagy and lysosome defects in DMD, but the endosomal pathway remained unstudied.

Purpose of the Study:

• To investigate endosomal pathway function in Duchenne muscular dystrophy.
• To identify molecular mechanisms underlying endosomal abnormalities in DMD.
• To explore potential therapeutic targets within the endosomal pathway for DMD.

Main Methods:

• Analysis of muscle cells from DMD patients and DMD animal models (mdx mice, GRMD dogs).
• Assessment of lysosome formation, acidification, and degradative function.
• Investigation of early endosome dynamics and Rab5 GTPase expression.
• Experimental manipulation including Rab5 knockdown and dystrophin restoration.

Main Results:

• Impaired lysosome formation, altered acidification, and reduced degradative function were observed in DMD muscle cells.
• Increased early endosomes were found in DMD patient cells and animal models.
• Abnormal Rab5 GTPase upregulation was identified as a key factor in DMD endosomal defects.
• Rab5 knockdown and dystrophin restoration normalized Rab5 levels and rescued endosomal abnormalities.

Conclusions:

• Duchenne muscular dystrophy is characterized by significant defects in the endosomal pathway, linked to dystrophin deficiency.
• Upregulation of Rab5 GTPase plays a critical role in these endosomal abnormalities.
• Targeting the endosomal pathway, specifically Rab5, presents a promising therapeutic strategy for DMD and may enhance existing treatment efficacy.